Zimbabwe is set to roll out a Shorter, Highly-effective, Oral Regimen for Rifampicin-resistant Tuberculosis (SHORRT therapy) which reduces the length of Treatment for Multi-Drug Resistant Tuberculosis (MDR-TB) from nearly two years, to, nine to 12 months and brings a major improvement in treatment outcomes and quality of life of patients. The nearly two-year-treatment regimen used to treat people… Read more on https://africa-newsroom.com/press/shorrt-drugresistant-tuberculosis-tb-treatment-on-cards?lang=en